Breaking

Russian International Reserves Fall $15.7 Billion in Week to Dec. 19
Tweet TWEET

Stellar Pharmaceuticals Appoints Chief Scientific Officer to

Stellar Pharmaceuticals Appoints Chief Scientific Officer to Support
Growing Product Portfolio 
Dr. Bernard Chiasson held Senior Medical Positions at United Health,
Amgen, Bayer Canada and Draxis Health 
MILTON, ONTARIO -- (Marketwire) -- 11/28/12 -- Stellar
Pharmaceuticals Inc. (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF)
("Stellar" or the "Company") and its operating division, Tribute
Pharmaceuticals announced today the appointment of Dr. Bernard
Chiasson, Ph.D. to the newly created position of Chief Scientific
Officer. Dr. Chiasson is a trained neuroscientist and pharmacologist
and will lead the scientific and regulatory affairs worldwide for
Stellar's proprietary products as well as its growing portfolio of
in-licensed products. 
Dr. Chiasson brings to Stellar the valuable combination of expertise
in medical science, business, and licensing, which he has translated
into strong growth for numerous global healthcare companies. Dr.
Chiasson recently served as Vice President, U.S. Strategic Regulatory
and Global Medical Services at OptumInsight (Life Sciences Group), a
division of UnitedHealth Group, a NYSE listed company with $100
billion in revenues. Prior to his position at OptumInsight, he was
Director, Regional Medical Liaisons and Medical Services, North
American Scientific Affairs for Amgen Canada, a division of Amgen, a
NASDAQ listed biotech with annual revenues over $15 billion. Dr.
Chiasson was also employed by Bayer Healthcare Canada, a division of
Bayer AG, a global pharmaceutical company with over $38 billion in
revenues, as Director, Scientific Development Biologic, Products for
Canada, as part of the Canada, Japan and Developing Markets Group. In
addition, he also served as Executive Director, Medical and
Regulatory Affairs at the then publicly-held Draxis Health and began
his industry career as a field-based Medical Liaison Specialist at
Novartis Pharmaceuticals Canada, a division of Novartis AG, a NYSE
listed healthcare company with $51 billion in annual revenues. 
"Dr. Chiasson's expertise, knowledge and relationships in the global
and North American healthcare market will be a great asset for
Stellar as we actively expand our in-licensed product portfolio in
the Canadian market and add additional distribution partners in
gl
obal markets including the U.S. for our proprietary Uracyst(R) and
NeoVisc(R) products," stated Rob Harris, President and CEO of
Stellar. 
About Stellar Pharmaceuticals Inc. 
Stellar and its operating division, Tribute Pharmaceuticals, is an
emerging Canadian specialty pharmaceutical company focused on the
acquisition, licensing, development and management of pharmaceutical
and healthcare products with its primary focus on the Canadian
market. 
Stellar markets Cambia(R) (diclofenac potassium for oral solution),
Bezalip(R) SR (bezafibrate), Soriatane(R) (acitretin), NeoVisc(R)
(1.0% sodium hyaluronate solution) a Uracyst(R) (sodium chondroitin
sulfate solution 2%), Collatamp G(R) and Gelfoam(R) in the Canadian
market. Additionally, NeoVisc(R) and Uracyst(R) are commercially
available and are sold globally through various international
partnerships. 
For further information on Stellar, visit www.stellarpharma.com, or
its operating division Tribute Pharmaceuticals, please visit
www.tributepharma.com. 
Stellar Pharmaceuticals' Forward Looking Statement 
This press release contains certain forward-looking statements about
Stellar as defined in the Private Securities Litigation Reform Act of
1995, which statements can be identified by the use of
forward-looking terminology, such as "may", "will", "expect",
"intend", "anticipate", "estimate", "predict", "plan" or "continue"
or the negative thereof or other variations thereon or comparable
terminology referring to future events or results. Forward-looking
statements, by their nature, are subject to risks and uncertainties,
Stellar actual results could differ materially from those anticipated
in these forward-looking statements as a result of numerous factors,
including general economic conditions, the ability of Stellar to
successfully integrate operations, and the timing of expenditures and
expansion opportunities, any of which could cause actual results to
vary materially from current results or anticipated future results.
See Stellar's reports filed with the Canadian Securities Regulatory
Authorities and the U.S. Securities and Exchange Commission from time
to time for cautionary statements identifying important factors with
respect to such forward-looking statements, including certain risks
and uncertainties, that could cause actual results to differ
materially from results referred to in forward-looking statements.
Stellar assumes no obligation to update the information contained in
this press release to update forward-looking statements to reflect
changed assumptions, the occurrence of anticipated events or changes
in future operating results, financial condition or business over
time. 


 
--  Soriatane and Bezalip are registered trademarks and under license from
    Actavis Group PTC ehf. 
--  Cambia is a registered trademark and under license from Nautilus
    Neurosciences, Inc. 
--  Collatamp G is a registered trademark an under license from EUSA Pharma
    (Europe) Limited. 
--  Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC,
    used under license by Pfizer Canada Inc. 

Contacts:
Stellar Pharmaceuticals Inc.
Scott Langille
CFO
519-434-1540
scott.langille@stellarpharma.com 
Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
705-445-9505
www.stellarpharma.com 
Hampton Growth
Robert Haag
877-368-3566
stellar@hamptongrowth.com
 
 
Press spacebar to pause and continue. Press esc to stop.